Navigation Links
Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia

MINNEAPOLIS, June 13, 2007 /PRNewswire/ -- Two studies presented today demonstrated that Rozerem did not affect body sway at peak plasma levels, nor did it impair middle-of-the-night balance, mobility or memory performance in patients who suffer from chronic insomnia. The results of the studies were presented at the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).

"These data are important because they show that ROZEREM may be a safe sleep medication for the many older adults who worry about their balance when they need to get up in the middle of the night. These studies also showed that the patients' memories were not affected by ROZEREM the next morning," said Gary Zammit, PhD, director, Sleep Disorders Institute, New York.

ROZEREM works differently from other prescription sleep medications. It specifically targets an area of the brain believed to be involved in the regulation of the body's normal sleep-wake cycle. It is the first prescription sleep medication that is not a controlled substance, and has shown no evidence of abuse or dependence in clinical studies.

ROZEREM Study Design 1: Effect on Body Sway

A total of 275 adults with chronic insomnia received ROZEREM 8 mg, zopiclone 7.5 mg or placebo in a 28-night double-blind treatment period. The primary endpoint was calculated area of center of pressure (COP), in cm2, recorded on the balance platform with eyes open. Zopiclone (Imovane(R) and Zimovane(R)) was used as a positive control. On night 14, patients were given a balance test one-and-a-half hours before dosing. Patients were then given their randomized medications and went to sleep. Approximately two hours after they had taken their treatments, the patients were awakened to take the balance test once again.

Results showed that at the time of predicted near-peak plasma levels, the effect of ROZEREM on body sway was no different from placebo
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/27/2015)... Calif. , Aug. 27, 2015 DURECT ... is scheduled to present at three upcoming healthcare conferences.  ... President and CEO, will present at the Rodman & ... a.m. Eastern time. The conference is being held at ... City . A live audio webcast of the ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
(Date:8/27/2015)... , Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, ... and corrected the multiple inaccuracies in the press ... regarding the recent rulings from the Patent Trial ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... CHICAGO, June 5, 2011 Nektar Therapeutics (Nasdaq: ... subpopulation of patients in a Phase 2 clinical study ...  A total of 33 women in the study with ... evaluable for response rate using either RECIST 1.0 criteria ...
... Health, Inc. (Nasdaq: GHDX ) today announced ... Society of Clinical Oncology (ASCO) Annual Meeting, including a ... Onco type DX® colon cancer Recurrence Score® (RS) ... II colon cancer.  The company also will present positive ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:8/27/2015)... Manistee, Michigan (PRWEB) , ... August 27, 2015 , ... ... Rehabilitation returned for the second year as sponsor of the “Music With A Mission” ... to raise money for music education programs in the underfunded school districts of Mendon ...
(Date:8/27/2015)... ... 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and a ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to the ... eight heroes who have made significant contributions in the field of rare blood cancers ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is pleased to announce ... in San Jose, CA. The first event dedicated to finding alternative solutions ... exists where battery development and energy storage innovation are concerned. Product developers, ...
(Date:8/27/2015)... Mirada, CA (PRWEB) , ... August 27, 2015 , ... ... Agency, into its La Tijera Clinic in Los Angeles. Licensed to practice Chinese Needle ... an emphasis on neuromuscular injuries and diseases. Dr. Priebe also practices in Healthpointe’s La ...
(Date:8/27/2015)... ... , ... More destinations and stores are becoming pet-friendly, making the family companion ... some tips to help your whole family travel safely and comfortably. , According to ... year. Amica is sharing the following tips from the American Society for the Prevention ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2
... YMCA of the USA (Y-USA) has,received a $6.8 ... (RWJF),to expand an innovative national initiative that helps ... Healthier Communities (PHC),encourages policy and environmental change in ... increased physical activity and,improved nutrition. The public ...
... FACP, FACEP (E), Executive Director, American Public Health Association , ... "At a time when national interest in reforming the health ... (APHA) applauds President-elect Obama for prioritizing health reform and selecting ... and Human Services, as well as the new White House ...
... Dec 11 The U.S. government, through the U.S. ... million and has deployed a Disaster Assistance Response Team (DART) ... assistance is in addition to more than $4.6 million for ... implementing in Zimbabwe. , , ...
... an electrical problem , , THURSDAY, Dec. 11 (HealthDay News) -- ... has been identified by U.S. researchers. , ... lead to new drugs and new ways of detecting the ... fibrillation is characterized by uncoordinated, chaotic and rapid beating of ...
... the age of 100 and never looking a day over 60 is ... And now, this information is available to everyone absolutely free. ... ... Natural Health News Report is offering a free download to the popular ...
... MONICA, Calif., Dec. 11 Less than 15% of U.S. ... insurers requiring every American to provide proof of private health ... a new poll. The poll, conducted by Consumer Watchdog, ... favor requiring a return on taxpayer-funded research that leads to ...
Cached Medicine News:Health News:YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation 2Health News:USAID Provides Additional $6.2M for Zimbabwe Cholera Outbreak 2Health News: Anti-Aging Miracle Physicians Have Been Waiting for is Finally Here : Free Book Available From Natural Health News Report Reveals the Secret to Staying Young 2Health News:New Poll Warns Daschle, Obama: Mandatory Health Insurance Big Loser With Public; Voters Want Return on Stem Cell Research 2Health News:New Poll Warns Daschle, Obama: Mandatory Health Insurance Big Loser With Public; Voters Want Return on Stem Cell Research 3
... Certified by an independent laboratory ... of Federal Standard 209E. Ergonomic ... fatique and back injuries. Clean ... requirements. Static-control chairs feature dissipative ...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... Vibratome Roto-Shake Genie is an all-in-one ... It performs five different mixing motions: ... rotating/rolling, as well as a combination ... precision-engineered moving portion of the Vibraotme ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Medicine Products: